From the very beginning, Roche’s visionary founder focused his company on innovation and on establishing an international presence. This multinational presence reinforces our ability to offer our healthcare solutions and to anticipate needs in all regions of the world.

Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to further drive personalised healthcare. Two-thirds of our Research and Development projects are being developed with companion diagnostics.

We are the world's number 1 in biotech with 17 biopharmaceuticals on the market. Over half of the compounds in our product pipeline are biopharmaceuticals, enabling us to deliver better-targeted therapies.

We have been at the forefront of cancer research and treatment for over 50 years, with medicines for breast, skin, colon, ovarian, lung and numerous other cancers.

We offer doctors profound information to guide treatments and to answer more patients’ questions than any other company. And our tests enable hospitals and labs to deliver that information quickly and reliably.

Basel, CH
Size (employees)
94,052 (est)+3%
Roche was founded in 1896 and is headquartered in Basel, CH

Key People at Roche

Severin Schwan

Severin Schwan

Chief Executive Officer Roche Group
Daniel O'Day

Daniel O'Day

CEO Roche Pharmaceuticals
Roland Diggelmann

Roland Diggelmann

CEO Roche Diagnostics
Alan Hippe

Alan Hippe

Chief Financial and IT Officer

Roche Office Locations

Roche has offices in Basel, South San Francisco
Basel, CH (HQ)
124 Grenzacherstrasse
South San Francisco, US
1 DNA Way

Roche Metrics

Roche Financial Metrics

Revenue (2015)

CHF48.1 b

Revenue growth (2014-15), %


Gross profit

CHF32.7 b

Gross profit margin (2015), %


Net income (2015)

CHF9.1 b

Market capitalization (22-Mar-2017)

CHF213.9 b

Closing share price (22-Mar-2017)

Roche's current market capitalization is CHF213.9 b.
Roche's revenue was reported to be CHF48.1 b in FY, 2015 which is a 1.4% increase from the previous period.
FY, 2013FY, 2014FY, 2015


CHF46.8 bCHF47.5 bCHF48.1 b

Revenue growth, %


Cost of goods sold

CHF11.9 bCHF13.4 bCHF15.5 b

Gross profit

CHF34.8 bCHF34.1 bCHF32.7 b

Gross profit Margin, %


Sales and marketing expense

CHF8.4 bCHF8.7 bCHF8.8 b

R&D expense

CHF9.3 bCHF9.9 bCHF9.6 b

General and administrative expense

CHF2.6 bCHF3.8 bCHF2.7 b

Operating expense total

CHF20.3 bCHF22.4 bCHF21.1 b

Interest expense

(CHF1.6 b)(CHF1.8 b)(CHF1.6 b)

Interest income

(CHF119 m)CHF246 m(CHF260 m)

Income tax expense

(CHF3.3 b)(CHF3 b)(CHF2.9 b)

Net Income

CHF11.4 bCHF9.5 bCHF9.1 b
FY, 2013FY, 2014FY, 2015

Cash From Operating Activities

CHF15.8 bCHF15.9 bCHF15.3 b

Roche Operating Metrics

Y, 2014Y, 2015Y, 2016

US FDA Breakthrough Therapy Designations


Drugs Approved by FDA


Major Approvals (US, EU, JP)


Roche Market Value History

Roche Revenue Breakdown

Roche Median Salaries

Source: 64 public H-1B filings from Roche

Roche Online Presence

Roche Company Life

You may also be interested in